VirnetX Holding Corporation — Form 8-K Summary
Reporting date: October 1, 2026. This is a current report announcing a financing arrangement, not a periodic financial-results filing.
Material agreement
VirnetX entered into an at-the-market offering agreement with Titan Partners Securities LLC as sales agent. Under the agreement, the company may sell up to $19,135,717 of common stock from time to time under its Form S-3 shelf registration statement. The company is not obligated to sell shares.
- Sales may be made on Nasdaq or another existing trading market, through a market maker, or, with the company’s prior written consent, in privately negotiated transactions.
- The agent’s commission is 3.0% of the gross sales price of shares sold.
- Net proceeds, if any, are intended for product development, marketing, and general corporate purposes, potentially including working capital, capital expenditures, and other corporate expenses.
Financial position and period comparison
The filing provides no revenue, profit, cash flow, margin, debt, liquidity, or other operating results, and no comparable-period figures. It does not state how many shares, if any, have been sold under the program. Any sales could result in dilution to existing shareholders.
Outlook, risks, and unusual items
The offering is a potential source of capital, but the amount and timing of proceeds are uncertain because sales are discretionary and depend on the agreement’s terms and market conditions. The company cautions that forward-looking statements are subject to risks, including changes in economic and financial conditions, capital and credit markets, and risks described in its other SEC filings. The company disclaims a duty to update forward-looking statements except as required by law.
Investor verification points
- Check subsequent SEC filings for shares sold, gross proceeds, commissions, and remaining offering capacity.
- Review the prospectus supplement and Sales Agreement for offering terms and termination provisions.
- Assess the potential dilution using actual shares issued and the company’s outstanding share count.
- Review later disclosures for how proceeds are used and for updates to the company’s financial condition and risk factors.